Paperonium

Type 1 diabetes · Diabetologia · 2025

Summary: when antibodies first appeared, kids whose relative got diabetes after birth differed. Table: not clearly.

The summary: diagnosedafter birth“significantly more often”Its own table: GADAno clear riseIts own table: two ormore kindsno clear riseDiagnosed before birth: GADAclear riseBefore birth: two or more kindsclear rise0.9 to 2.1×0.92.40.8×1×1.5×2×2.5×3×same odds
The summary:diagnosedafter birth“significantlymore often”Its owntable: GADAno clear riseIts own table: twoor more kindsno clear riseDiagnosed beforebirth: GADAclear riseBefore birth: two ormore kindsclear rise0.9 to 2.1×0.92.40.7×1×2×3×same odds

When antibodies first appeared: each group versus children with no affected parent or sibling

The paper says

The paper’s summary says when children first made antibodies against their insulin-making cells, the 87 whose parent or sibling got type 1 diabetes after their birth “significantly more often” had one kind, GADA, and two or more kinds, than the 1,102 with no affected parent or sibling.

Its own data show

Its tables, at that same point: GADA in 59.8% of the 87 vs 52.5% of the 1,102; two or more kinds in 31.0% vs 23.3%. As odds (having it versus not): 1.3 times as high (a range of 0.9 to 2.1) and 1.5 times (0.9 to 2.4). Its results text: “no difference was observed”.

A range is the span of values the data can’t rule out; 1 means equal odds. “Significantly” means chance alone would rarely produce the gap, which needs the whole range above 1. Both ranges here start at 0.9. The paper’s own discussion says these children stood out only later, during follow-up; the summary, which most people read, says otherwise.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative · Diabetologia (2025) · doi:10.1007/s00125-025-06573-6